Ligand Pharmaceuticals, Inc. (LGND) Reports Q4 Earnings of $0.24, Offers FY12 Sales Guidance
LGND Hot Sheet
EPS Growth %: -85.4%Financial Fact:
Income (loss) from continuing operations: -487K
Today's EPS Names:
TARO, BRLI, TLB, More
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q4 EPS of $0.24, versus $0.12 reported last year. Revenue for the quarter came in at $12.9 million, versus $3.9 million reported last year.
For 2012, Ligand currently estimates total revenues to be approximately $30 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
For 2012, Ligand currently estimates total revenues to be approximately $30 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Toro Co. (TTC) Tops Q1 EPS by 13c; Guides FY12 EPS Above Views; to Split Stock
- Signet Jewelers (SIG) Tops Q1 EPS by 5c; Guides Q2 Below the Street
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
